What is the current valuation of the Infertility Market as of 2024?

The Infertility Market was valued at approximately 2035.28 USD Million in 2024. Read More

What is the projected market valuation for the Infertility Market in 2035?

The market is projected to reach a valuation of around 7671.5 USD Million by 2035. Read More

What is the expected CAGR for the Infertility Market during the forecast period 2025 - 2035?

The expected CAGR for the Infertility Market during the forecast period 2025 - 2035 is 12.82%. Read More

Which treatment type segment is expected to have the highest valuation in 2035?

The In Vitro Fertilization segment is anticipated to reach approximately 3000.0 USD Million by 2035. Read More

How does the market for Female Factor Infertility compare to Male Factor Infertility in 2035?

By 2035, the Female Factor Infertility segment is projected to be valued at around 3200.0 USD Million, significantly higher than the Male Factor Infertility segment at approximately 1200.0 USD Million. Read More

What are the projected valuations for Assisted Reproductive Technology segments in 2035?

In 2035, the Egg Donation segment is expected to reach about 3871.5 USD Million, while Cryopreservation is projected at 1200.0 USD Million. Read More

Which age group is expected to contribute the most to the Infertility Market by 2035?

The age group of 25 to 34 is projected to contribute significantly, with a valuation of approximately 3030.75 USD Million by 2035. Read More

What role do fertility clinics play in the Infertility Market?

Fertility clinics are expected to be a major contributor, with a projected valuation of around 3000.0 USD Million by 2035. Read More

How is the market for telemedicine expected to evolve by 2035?

The telemedicine segment is projected to grow, reaching an estimated valuation of 971.5 USD Million by 2035. Read More

Who are the key players in the Infertility Market?

Key players in the Infertility Market include CooperSurgical, Merck KGaA, Ferring Pharmaceuticals, and others. Read More

Infertility Market

ID: MRFR/LS/4687-HCR

100 Pages

Rahul Gotadki

Last Updated: May 15, 2026

Infertility Market Research Report By Treatment Type (Assisted Reproductive Technology, Hormone Therapy, Surgery, Fertility Preservation), By End User (Hospitals, Fertility Clinics, Home Care Settings), By Gender (Female, Male), By Cause of Infertility (Ovulatory Disorders, Uterine or Cervical Abnormalities, Tubal Factors, Male Factor Infertility) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Methodology Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Treatment Type (USD Million)
  1. 4.1.1 In Vitro Fertilization
  2. 4.1.2 Intracytoplasmic Sperm Injection
  3. 4.1.3 Artificial Insemination
  4. 4.1.4 Ovulation Induction
2. 4.2 Healthcare, BY Cause of Infertility (USD Million)
  1. 4.2.1 Male Factor Infertility
  2. 4.2.2 Female Factor Infertility
  3. 4.2.3 Unexplained Infertility
  4. 4.2.4 Combined Infertility
3. 4.3 Healthcare, BY Age Group (USD Million)
  1. 4.3.1 Under 25
  2. 4.3.2 25 to 34
  3. 4.3.3 35 to 44
  4. 4.3.4 45 and Above
4. 4.4 Healthcare, BY Assisted Reproductive Technology (USD Million)
  1. 4.4.1 Cryopreservation
  2. 4.4.2 Preimplantation Genetic Testing
  3. 4.4.3 Sperm Donation
  4. 4.4.4 Egg Donation
5. 4.5 Healthcare, BY Healthcare Setting (USD Million)
  1. 4.5.1 Fertility Clinics
  2. 4.5.2 Hospitals
  3. 4.5.3 Home Care
  4. 4.5.4 Telemedicine
6. 4.6 Healthcare, BY Region (USD Million)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 CooperSurgical (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck KGaA (DE)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Ferring Pharmaceuticals (CH)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Irvine Scientific (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Vitrolife (SE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Reproductive Health Technologies (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 OvaScience (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Genea Limited (AU)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 HRC Fertility (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TREATMENT TYPE
4. 6.4 US MARKET ANALYSIS BY CAUSE OF INFERTILITY
5. 6.5 US MARKET ANALYSIS BY AGE GROUP
6. 6.6 US MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
7. 6.7 US MARKET ANALYSIS BY HEALTHCARE SETTING
8. 6.8 CANADA MARKET ANALYSIS BY TREATMENT TYPE
9. 6.9 CANADA MARKET ANALYSIS BY CAUSE OF INFERTILITY
10. 6.10 CANADA MARKET ANALYSIS BY AGE GROUP
11. 6.11 CANADA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
12. 6.12 CANADA MARKET ANALYSIS BY HEALTHCARE SETTING
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY TREATMENT TYPE
15. 6.15 GERMANY MARKET ANALYSIS BY CAUSE OF INFERTILITY
16. 6.16 GERMANY MARKET ANALYSIS BY AGE GROUP
17. 6.17 GERMANY MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
18. 6.18 GERMANY MARKET ANALYSIS BY HEALTHCARE SETTING
19. 6.19 UK MARKET ANALYSIS BY TREATMENT TYPE
20. 6.20 UK MARKET ANALYSIS BY CAUSE OF INFERTILITY
21. 6.21 UK MARKET ANALYSIS BY AGE GROUP
22. 6.22 UK MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
23. 6.23 UK MARKET ANALYSIS BY HEALTHCARE SETTING
24. 6.24 FRANCE MARKET ANALYSIS BY TREATMENT TYPE
25. 6.25 FRANCE MARKET ANALYSIS BY CAUSE OF INFERTILITY
26. 6.26 FRANCE MARKET ANALYSIS BY AGE GROUP
27. 6.27 FRANCE MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
28. 6.28 FRANCE MARKET ANALYSIS BY HEALTHCARE SETTING
29. 6.29 RUSSIA MARKET ANALYSIS BY TREATMENT TYPE
30. 6.30 RUSSIA MARKET ANALYSIS BY CAUSE OF INFERTILITY
31. 6.31 RUSSIA MARKET ANALYSIS BY AGE GROUP
32. 6.32 RUSSIA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
33. 6.33 RUSSIA MARKET ANALYSIS BY HEALTHCARE SETTING
34. 6.34 ITALY MARKET ANALYSIS BY TREATMENT TYPE
35. 6.35 ITALY MARKET ANALYSIS BY CAUSE OF INFERTILITY
36. 6.36 ITALY MARKET ANALYSIS BY AGE GROUP
37. 6.37 ITALY MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
38. 6.38 ITALY MARKET ANALYSIS BY HEALTHCARE SETTING
39. 6.39 SPAIN MARKET ANALYSIS BY TREATMENT TYPE
40. 6.40 SPAIN MARKET ANALYSIS BY CAUSE OF INFERTILITY
41. 6.41 SPAIN MARKET ANALYSIS BY AGE GROUP
42. 6.42 SPAIN MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
43. 6.43 SPAIN MARKET ANALYSIS BY HEALTHCARE SETTING
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY TREATMENT TYPE
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY CAUSE OF INFERTILITY
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY AGE GROUP
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY HEALTHCARE SETTING
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY TREATMENT TYPE
51. 6.51 CHINA MARKET ANALYSIS BY CAUSE OF INFERTILITY
52. 6.52 CHINA MARKET ANALYSIS BY AGE GROUP
53. 6.53 CHINA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
54. 6.54 CHINA MARKET ANALYSIS BY HEALTHCARE SETTING
55. 6.55 INDIA MARKET ANALYSIS BY TREATMENT TYPE
56. 6.56 INDIA MARKET ANALYSIS BY CAUSE OF INFERTILITY
57. 6.57 INDIA MARKET ANALYSIS BY AGE GROUP
58. 6.58 INDIA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
59. 6.59 INDIA MARKET ANALYSIS BY HEALTHCARE SETTING
60. 6.60 JAPAN MARKET ANALYSIS BY TREATMENT TYPE
61. 6.61 JAPAN MARKET ANALYSIS BY CAUSE OF INFERTILITY
62. 6.62 JAPAN MARKET ANALYSIS BY AGE GROUP
63. 6.63 JAPAN MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
64. 6.64 JAPAN MARKET ANALYSIS BY HEALTHCARE SETTING
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY TREATMENT TYPE
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY CAUSE OF INFERTILITY
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY AGE GROUP
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY HEALTHCARE SETTING
70. 6.70 MALAYSIA MARKET ANALYSIS BY TREATMENT TYPE
71. 6.71 MALAYSIA MARKET ANALYSIS BY CAUSE OF INFERTILITY
72. 6.72 MALAYSIA MARKET ANALYSIS BY AGE GROUP
73. 6.73 MALAYSIA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
74. 6.74 MALAYSIA MARKET ANALYSIS BY HEALTHCARE SETTING
75. 6.75 THAILAND MARKET ANALYSIS BY TREATMENT TYPE
76. 6.76 THAILAND MARKET ANALYSIS BY CAUSE OF INFERTILITY
77. 6.77 THAILAND MARKET ANALYSIS BY AGE GROUP
78. 6.78 THAILAND MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
79. 6.79 THAILAND MARKET ANALYSIS BY HEALTHCARE SETTING
80. 6.80 INDONESIA MARKET ANALYSIS BY TREATMENT TYPE
81. 6.81 INDONESIA MARKET ANALYSIS BY CAUSE OF INFERTILITY
82. 6.82 INDONESIA MARKET ANALYSIS BY AGE GROUP
83. 6.83 INDONESIA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
84. 6.84 INDONESIA MARKET ANALYSIS BY HEALTHCARE SETTING
85. 6.85 REST OF APAC MARKET ANALYSIS BY TREATMENT TYPE
86. 6.86 REST OF APAC MARKET ANALYSIS BY CAUSE OF INFERTILITY
87. 6.87 REST OF APAC MARKET ANALYSIS BY AGE GROUP
88. 6.88 REST OF APAC MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
89. 6.89 REST OF APAC MARKET ANALYSIS BY HEALTHCARE SETTING
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY TREATMENT TYPE
92. 6.92 BRAZIL MARKET ANALYSIS BY CAUSE OF INFERTILITY
93. 6.93 BRAZIL MARKET ANALYSIS BY AGE GROUP
94. 6.94 BRAZIL MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
95. 6.95 BRAZIL MARKET ANALYSIS BY HEALTHCARE SETTING
96. 6.96 MEXICO MARKET ANALYSIS BY TREATMENT TYPE
97. 6.97 MEXICO MARKET ANALYSIS BY CAUSE OF INFERTILITY
98. 6.98 MEXICO MARKET ANALYSIS BY AGE GROUP
99. 6.99 MEXICO MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
100. 6.100 MEXICO MARKET ANALYSIS BY HEALTHCARE SETTING
101. 6.101 ARGENTINA MARKET ANALYSIS BY TREATMENT TYPE
102. 6.102 ARGENTINA MARKET ANALYSIS BY CAUSE OF INFERTILITY
103. 6.103 ARGENTINA MARKET ANALYSIS BY AGE GROUP
104. 6.104 ARGENTINA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
105. 6.105 ARGENTINA MARKET ANALYSIS BY HEALTHCARE SETTING
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT TYPE
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY CAUSE OF INFERTILITY
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY AGE GROUP
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY HEALTHCARE SETTING
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT TYPE
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY CAUSE OF INFERTILITY
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY AGE GROUP
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY HEALTHCARE SETTING
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT TYPE
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY CAUSE OF INFERTILITY
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY AGE GROUP
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY HEALTHCARE SETTING
122. 6.122 REST OF MEA MARKET ANALYSIS BY TREATMENT TYPE
123. 6.123 REST OF MEA MARKET ANALYSIS BY CAUSE OF INFERTILITY
124. 6.124 REST OF MEA MARKET ANALYSIS BY AGE GROUP
125. 6.125 REST OF MEA MARKET ANALYSIS BY ASSISTED REPRODUCTIVE TECHNOLOGY
126. 6.126 REST OF MEA MARKET ANALYSIS BY HEALTHCARE SETTING
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY TREATMENT TYPE, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY TREATMENT TYPE, 2024 TO 2035 (USD Million)
135. 6.135 HEALTHCARE, BY CAUSE OF INFERTILITY, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY CAUSE OF INFERTILITY, 2024 TO 2035 (USD Million)
137. 6.137 HEALTHCARE, BY AGE GROUP, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY AGE GROUP, 2024 TO 2035 (USD Million)
139. 6.139 HEALTHCARE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2024 TO 2035 (USD Million)
141. 6.141 HEALTHCARE, BY HEALTHCARE SETTING, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY HEALTHCARE SETTING, 2024 TO 2035 (USD Million)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.2.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.2.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.2.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.3.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.3.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.3.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.3.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.4.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.4.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.4.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.4.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.5.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.5.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.5.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.5.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.6.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.6.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.6.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.6.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.7.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.7.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.7.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.7.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.8.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.8.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.8.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.8.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.9.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.9.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.9.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.9.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.10.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.10.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.10.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.10.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.11.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.11.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.11.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.11.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.12.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.12.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.12.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.12.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.13.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.13.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.13.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.13.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.14.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.14.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.14.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.14.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.15.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.15.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.15.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.15.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.16.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.16.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.16.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.16.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.17.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.17.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.17.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.17.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.18.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.18.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.18.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.18.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.19.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.19.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.19.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.19.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.20.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.20.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.20.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.20.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.21.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.21.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.21.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.21.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.22.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.22.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.22.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.22.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.23.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.23.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.23.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.23.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.24.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.24.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.24.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.24.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.25.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.25.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.25.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.25.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.26.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.26.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.26.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.26.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.27.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.27.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.27.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.27.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.28.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.28.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.28.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.28.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.29.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.29.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.29.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.29.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TREATMENT TYPE, 2025-2035 (USD Million)
  2. 7.30.2 BY CAUSE OF INFERTILITY, 2025-2035 (USD Million)
  3. 7.30.3 BY AGE GROUP, 2025-2035 (USD Million)
  4. 7.30.4 BY ASSISTED REPRODUCTIVE TECHNOLOGY, 2025-2035 (USD Million)
  5. 7.30.5 BY HEALTHCARE SETTING, 2025-2035 (USD Million)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Treatment Type (USD Million, 2025-2035)

In Vitro Fertilization
Intracytoplasmic Sperm Injection
Artificial Insemination
Ovulation Induction

Healthcare By Cause of Infertility (USD Million, 2025-2035)

Male Factor Infertility
Female Factor Infertility
Unexplained Infertility
Combined Infertility

Healthcare By Age Group (USD Million, 2025-2035)

Under 25
25 to 34
35 to 44
45 and Above

Healthcare By Assisted Reproductive Technology (USD Million, 2025-2035)

Cryopreservation
Preimplantation Genetic Testing
Sperm Donation
Egg Donation

Healthcare By Healthcare Setting (USD Million, 2025-2035)

Fertility Clinics
Hospitals
Home Care
Telemedicine

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓